Introducing Point Mutations into Human Pluripotent Stem Cells Using Seamless Genome Editing
May 10th, 2020
4.1K views
Here, we describe a detailed method for seamless gene editing in human pluripotent stem cells using a piggyBac-based donor plasmid and the Cas9 nickase mutant. Two point mutations were introduced into exon 8 of the hepatocyte nuclear factor 4 alpha (HNF4α) locus in human embryonic stem cells (hESCs).
Overview
This article presents a detailed protocol for seamless gene editing in human pluripotent stem cells using a piggyBac-based donor plasmid and Cas9 nickase mutant. The method successfully introduces two point mutations into the HNF4α locus in human embryonic stem cells.
Key Study Components
Area of Science
- Gene Editing
- Stem Cell Biology
- Genomics
Background
- Gene editing in human pluripotent stem cells is complex.
- Paired Cas9 nickase provides a reliable editing method.
- Seamless genomic editing is advantageous for precise modifications.
- Efficient genotyping screening is crucial for successful editing.
Purpose of Study
- To develop a method for precise gene editing in human pluripotent stem cells.
- To introduce specific mutations in the HNF4α gene.
- To enhance the efficiency of selecting edited cells.
Methods Used
- Maintenance of stem cells on recombinant laminin surfaces.
- Nucleofection of cells with Cas9 and targeting vector plasmids.
- Use of puromycin selection to isolate successfully edited cells.
- Genotyping and sequencing to confirm successful edits.
Main Results
- Two point mutations were successfully introduced into the HNF4α locus.
- Cells maintained pluripotent characteristics post-editing.
- Efficient selection and genotyping methods were established.
- Edited cells expressed key pluripotent markers.
Conclusions
- The protocol enables precise gene editing in human pluripotent stem cells.
- It provides a foundation for studying gene function and differentiation.
- Future applications include investigating specific gene roles in development.
Frequently Asked Questions
What is the main advantage of this gene editing protocol?
The main advantage is the seamless genomic editing, which allows for precise modifications without leaving unwanted sequences.
How are the edited cells selected?
Edited cells are selected using puromycin, which helps isolate cells that have successfully integrated the desired mutations.
What markers are used to confirm pluripotency?
Markers such as Nanog, Oct4, SSEA-4, and TRA-160 are used to confirm that the edited cells maintain pluripotent characteristics.
What is the role of ROCK inhibitor in the protocol?
ROCK inhibitor is used to enhance cell survival and promote cell-to-cell contact during the early stages post-nucleofection.
How is the success of gene editing verified?
Success is verified through genotyping and Sanger sequencing of the edited regions to confirm the introduction of the desired mutations.
Can this method be applied to other genes?
Yes, this method can be adapted to target other genes of interest in human pluripotent stem cells.
Executive Industry Relevance
Seamless genome editing in human pluripotent stem cells enables precise interrogation of gene function and disease modeling at the earliest stages of drug discovery. The protocol's efficiency and reliability in introducing point mutations at the HNF4α locus support high-confidence target validation and mechanistic de-risking. This capability strengthens translational continuity from discovery biology to preclinical research, directly impacting portfolio prioritization.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables precise introduction of disease-relevant mutations for functional genomics studies.
- Supports robust target validation by generating isogenic cell lines with defined genetic alterations.
- Facilitates mechanistic de-risking by allowing direct assessment of gene function in human cellular contexts.
- Improves predictive confidence for downstream therapeutic hypothesis testing.
Screening & Assay Development
- Provides validated, genetically defined cell systems for assay development and compound screening.
- Ensures reproducibility and standardization through seamless editing and rigorous genotyping.
- Enables quantitative readouts by confirming precise genomic modifications via PCR and sequencing.
- Supports scalable generation of cell lines for high-throughput screening platforms.
Translational & Preclinical Research
- Aligns engineered cell models with disease-relevant genotypes for translational biomarker studies.
- Maintains pluripotency and differentiation potential, supporting continuity into preclinical validation.
- Reduces biological risk by confirming genetic and phenotypic fidelity of edited lines.
- Enables risk-adjusted advancement decisions based on validated genetic models.
Pipeline & Workflow Integration
This genome editing protocol integrates at the interface of early discovery and preclinical model development, enabling seamless transition from target validation to disease modeling.
- Discovery Biology: Supports hypothesis testing and pathway clarification by enabling targeted gene modification.
- Screening: Delivers reproducible, genetically defined cell lines for assay readiness and quantitative evaluation.
- Analytics: Provides robust genotyping and sequencing outputs for confident comparison of edited versus parental lines.
- Translational Research: Bridges discovery and preclinical research by generating models with disease-relevant mutations.
- Enterprise Reuse: Establishes a reusable platform for generating custom-edited pluripotent stem cell lines across multiple targets.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
- Operational Value: Standardizes genome editing workflows for reproducibility and scalability.
- Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio management.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of genetically validated targets.
Implementation Considerations
- Requires expertise in stem cell culture, nucleofection, and molecular genotyping.
- Needs access to electroporation devices, high-quality plasmids, and sequencing infrastructure.
- Demands rigorous cross-team standardization for cell handling and selection protocols.
- Adaptation may be needed for different gene targets or cell line backgrounds.
- Cell viability and confluency must be closely monitored during selection and expansion phases.
Biopharma FAQs
Why does null hypothesis testing matter for HNF4α point mutation validation?
Null hypothesis testing enables objective assessment of whether introduced HNF4α mutations produce functional changes, supporting rigorous target validation and reducing mechanistic uncertainty in early discovery.
How does independent variable isolation fit the genome editing workflow?
By generating isogenic cell lines differing only at the edited locus, the protocol isolates the effect of specific point mutations, clarifying causal relationships for discovery-stage decision making.
What do quantitative PCR and sequencing measurements enable in this protocol?
Quantitative PCR and Sanger sequencing confirm precise genomic modifications, enabling confident selection of correctly edited clones and supporting reproducible downstream analyses.
Why are replication requirements critical for cross-functional stem cell editing projects?
Replication ensures that genome editing and selection steps yield consistent, validated cell lines, facilitating reliable handoff between discovery, screening, and translational teams.
What statistical analysis capabilities are required before implementing genotyping screens?
Robust statistical analysis of genotyping and sequencing data is essential to distinguish true positive edits from background, ensuring only accurately modified clones advance in the R&D pipeline.
